Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically ...

Explore a rare case of systemic mastocytosis in a young adult, highlighting its role in unexplained osteoporosis and the need ...

THB335 showed dose-dependent serum tryptase reductions from 13% to 84% at Day 15, supporting its advancement to Phase 2 in ...

James made a notable change in their assessment of Third Harmonic (NASDAQ:HLIT) Bio (NASDAQ:THRD), downgrading the biotechnology company's stock rating from Outperform to Market Perform. According to ...

Third Harmonic Bio (THRD) announced results from its Phase 1 single and multiple ascending dose clinical trial of THB335 in healthy volunteers.

A mild positive food effect was observed as well. Pharmacodynamics Dose-dependent reductions in serum tryptase, a biomarker of mast cell activation, were observed in the MAD cohorts, with mean ...

A new case report was published in Oncoscience's Volume 12 on February 4, 2025, titled “Breaking point: Systemic mastocytosis manifesting as severe osteoporosis.” ...

Blueprint Medicines Corporation (NASDAQ: BPMC) today reported financial results and provided a business update for the fourth ...

This report highlights the diagnostic challenges of SM, emphasize its underrecognized role in osteoporosis and fragility fractures, and advocates for ...

Blueprint Medicines Corporation ( NASDAQ: BPMC) Q4 2024 Earnings Conference Call February 13, 2025 8:00 AM ET ...